{"disease":{"id":"her2-normal","name":"her2 normal"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01864746","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"GBG Forschungs GmbH","has_results":true},{"nct_id":"NCT01328249","title":"Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT03410927","title":"A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}